LTRN Lantern Pharma Inc.

Nasdaq lanternpharma.com


$ 4.05 $ 0.00 (0 %)    

Monday, 20-Oct-2025 09:40:26 EDT
QQQ $ 608.95 $ 1.82 (0.3 %)
DIA $ 463.88 $ 0.46 (0.1 %)
SPY $ 668.49 $ 1.17 (0.18 %)
TLT $ 91.45 $ -0.01 (-0.01 %)
GLD $ 397.05 $ -0.31 (-0.1 %)
$ 3.97
$ 4.21
$ 3.97 x 90
$ 4.05 x 187
-- - --
$ 2.55 - $ 6.12
211,852
na
42.87M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-20-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-01-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 05-03-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lantern-pharmas-lp-184-meets-all-phase-1a-endpoints-shows-clinical-benefit-in-hard-to-treat-cancers-and-advances-to-phase-2-trials

LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both mono...

 lantern-pharma-completes-type-c-meeting-with-fda-advancing-pediatric-cns-cancer-trial-including-atypical-teratoid-rhabdoid-tumor

Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that ...

 lantern-pharma-q2-eps-040-beats-048-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48...

 lantern-pharmas-starlight-therapeutics-receives-fda-clearance-its-ind-for-phase-ib2a-glioblastoma-multiforme-trial

Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progressionGBM...

 lantern-pharma-unveils-predictbbbai-with-94-accuracy-revolutionizing-cns-drug-development-through-real-time-ai

Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Dev...

 lantern-pharma-completes-early-enrollment-in-japan-for-lung-cancer-trial-targeting-never-smokers

Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its propr...

 lantern-pharma-reports-complete-metabolic-response-in-a-heavily-pre-treated-lymphoma-patient-with-lp-284-in-its-phase-1-clinical-trial

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prio...

 lantern-pharma-secures-eu-patent-allowance-for-lp-284-expanding-global-ip-for-b-cell-lymphoma-therapy

The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico.LP-284 has the pote...

 lantern-pharma-launches-ai-module-trained-on-221-clinical-trials-to-predict-efficacy-of-dna-damaging-agent-combinations-platform-already-guided-fda-cleared-phase-1b2-trial-in-triple-negative-breast-cancer

The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will init...

 lantern-pharma-enters-1553m-at-the-market-offering-agreement-with-thinkequity

On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the ...

 lantern-pharma-announces-preclinical-data-for-lp-184-in-atypical-teratoid-rhabdoid-tumors-rare-and-aggressive-pediatric-brain-cancer

Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION